Skip to main content
H.R. 5133 116th Congress House

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

Official title: To amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.

Introduced: November 20, 2019 See on congress.gov
Commerce Administrative remediesCivil actions and liabilityCompetition and antitrustConsumer affairs
More subjectsShow fewer subjects
Drug safety, medical device, and laboratory regulationFederal Trade Commission (FTC)Health care costs and insuranceInflation and pricesIntellectual propertyJudicial review and appealsManufacturingPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 8 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 24, 2020
Placed on the Union Calendar, Calendar No. 578.
Dec 24, 2020
Reported by the Committee on Judiciary. H. Rept. 116-695.
Nov 21, 2019
Ordered to be Reported.
Nov 21, 2019
Committee Consideration and Mark-up Session Held.
Nov 19, 2019
Subcommittee on Antitrust, Commercial, and Administrative Law Discharged.
Nov 18, 2019
Introduced in House
Nov 18, 2019
Referred to the House Committee on the Judiciary.
Nov 18, 2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action December 24, 2020

Placed on the Union Calendar, Calendar No. 578.

 Plain-English summary Congressional Research Service

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.

 Related & companion bills 3
  • S 1416 Affordable Prescriptions for Patients Act of 2019
  • HR 2486 FUTURE Act
  • HR 4398 Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 5
All 5 Democratic 2 Republican 1
R
Cline, Ben
Virginia · Nov 20, 2019
 D
McBath, Lucy
Georgia · Nov 20, 2019
Collins, Doug
· Nov 18, 2019
 D
Nadler, Jerrold
New York · Nov 18, 2019
SENSENBRENNER, F.
· Nov 18, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5133: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-5133/
MLA
"H.R. 5133: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-5133/.
Bluebook (legal)
H.R. 5133, 116th Cong. (2026), https://openamerica.io/bill/116-HR-5133/.
Markdown link
[H.R. 5133: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019](https://openamerica.io/bill/116-HR-5133/)
Report a problem